ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 16, 2017

Primary Completion Date

February 19, 2020

Study Completion Date

February 10, 2021

Conditions
Coronary DiseaseMyocardial Infarction
Interventions
DRUG

Tocilizumab

Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.

DRUG

Sodium chloride 0.9%

Placebo: Sodium chloride 0.9%; 100 ml i.v. once.

Trial Locations (3)

7006

St. Olav Hospital, Trondheim

0424

Oslo University Hospital, Rikshospitalet, Oslo

Oslo University Hospital, Ullevål, Oslo

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

University of Oslo

OTHER

collaborator

Norwegian University of Science and Technology

OTHER

lead

Oslo University Hospital

OTHER

NCT03004703 - ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial | Biotech Hunter | Biotech Hunter